Ablynx Initiates Phase II Clinical Trial For ALX-0081

Links shared publicly online about this topic.

  • 1,777
    total visits

Ablynx Initiates Phase II Clinical Trial For ALX-0081

medicalnewstoday.com —

Ablynx [euronext brussels: ablx] announced the initiation of a phase ii study for its anti-thrombotic nanobody® alx-0081, a first-in-class nanobody® targeting von willebrand factor (vwf).

View full resource at medicalnewstoday.com

Tags: Clinical Trial

  • Share

Most Recently Shared on September 3, 2009 at 6:31 am By:

HeartsHealth Heart Health

MedicalNewsToday: Ablynx Initiates Phase II Clinical Trial For ALX-0081 http://bit.ly/jm14u Full http://bit.ly/4oOXth

3 years ago...

Reply

Retweet

Favorite

Also Shared By:

MNT Cardiovascular MNT Cardiovascular

Advertisement